Women make up more than half of the population, yet they remain significantly underrepresented in psychedelic research. At ICPR 2026, we spoke with neuroscientist Grace Blest-Hopley about the gender gap in psychedelic science, the importance of studying menstrual cycles, pregnancy, menopause, and women’s mental health, and how the field can become more inclusive and scientifically rigorous.

On 7 May 2026, policymakers, researchers, clinicians, people with lived experience, and civil society organisations gathered in Brussels for the inaugural meeting of the European Forum of National Psychedelic Societies. The meeting marked an important milestone in building a coordinated European movement to expand safe, evidence-based access to psychedelic-assisted therapies.

Watch Drugreporter’s short documentary, filmed at the seventh Interdisciplinary Conference on Psychedelic Research (ICPR) 2026 in Haarlem, the Netherlands, exploring how psychedelic science is evolving through conversations on Indigenous knowledge, therapy, consciousness, culture and the future of the field.

At ICPR 2024, we talked to psychologist and psychotherapist Marc B. Aixalà about how so-called “bad trips” can be reframed as difficult but potentially transformative experiences, and the importance of integration in psychedelic therapy.

On 7 May 2026, PAREA convened the first European Forum of National Psychedelic Societies in Brussels, bringing together representatives from organisations in 25 countries working on psychedelic research, policy, and access across Europe. Watch key presentations on the state of psychedelic access in Europe, filmed by Drugreporter.

How could evidence-based psychedelic therapies help address war-related mental health challenges in Ukraine, particularly PTSD among veterans? This was the main question of the European Parliament event held on 6 May, which Drugreporter captured on video in its entirety. Watch the full session now!

Tadeusz Hawrot is the founder of the Psychedelic Access and Research European Alliance (PAREA), a Brussels-based initiative working to prepare Europe for the integration of psychedelic-assisted therapies into healthcare systems. In this interview, he reflects on the policy landscape, regulatory challenges, and the future of access to these emerging treatments in the EU.

Jeremy Rudy, founder of the Sabba Collective, explains how psychedelic therapy can be integrated into society safely and responsibly — from education to policy.

We spoke with Pavel Bém, a Czech psychiatrist and former mayor of Prague in Vienna during the 69th session of the Commission on Narcotic Drugs (CND) about the country’s latest reforms—from cannabis regulation to psychedelic therapy—and what they mean for the future of drug policy in Europe.

Senator Jeff Steinborn is the sponsor of the Medical Psilocybin Act in New Mexico, a visionary step toward expanding access to psychedelic therapy. In this conversation, filmed at the Psychedelic Science 2025 conference in Denver, he discusses why legislative action was necessary, how to ensure inclusion for marginalized communities, and what benchmarks will define success as New Mexico opens its first healing centers.